NO20074509L - Kombinasjon av organiske forbindelser - Google Patents
Kombinasjon av organiske forbindelserInfo
- Publication number
- NO20074509L NO20074509L NO20074509A NO20074509A NO20074509L NO 20074509 L NO20074509 L NO 20074509L NO 20074509 A NO20074509 A NO 20074509A NO 20074509 A NO20074509 A NO 20074509A NO 20074509 L NO20074509 L NO 20074509L
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- combination
- angiotensin
- organic compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Foreliggende oppfinnelse angår en kombinasjon som innbefatter: (i) en renininhibitor eller et farmasøytisk akseptabelt salt derav; (ii) en nøytral endopeptidase (NEP) inhibitor eller et farmasøytisk akseptabelt salt derav; og eventuelt minst et terapeutisk middel valgt fra gruppen som består av (a) et diuretisk middel eller et farmasøytisk akseptabelt salt derav; og (b) en angiotensin H reseptorblokkerer (ARB) eller et farmasøytisk akseptabelt salt derav for å hindre, forsinke utbruddet av og/eller behandle en sykdom eller tilstand mediert av angiotensin II og/eller NEP aktivitet, hvilken fremgangsmåte innbefatter administrering til et varmblodig dyr, som trenger det, en terapeutisk effektiv mengde av en kombinasjon ifølge oppfinnelsen.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65232505P | 2005-02-11 | 2005-02-11 | |
US65510205P | 2005-02-22 | 2005-02-22 | |
US67009005P | 2005-04-11 | 2005-04-11 | |
PCT/US2006/004401 WO2006086456A2 (en) | 2005-02-11 | 2006-02-09 | Combination of organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20074509L true NO20074509L (no) | 2007-11-12 |
Family
ID=36793671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20074509A NO20074509L (no) | 2005-02-11 | 2007-09-06 | Kombinasjon av organiske forbindelser |
Country Status (18)
Country | Link |
---|---|
US (1) | US20080119557A1 (no) |
EP (1) | EP1863467A2 (no) |
JP (1) | JP2008530101A (no) |
KR (1) | KR20070102544A (no) |
AR (1) | AR053809A1 (no) |
AU (1) | AU2006212772B2 (no) |
BR (1) | BRPI0606996A2 (no) |
CA (1) | CA2596485A1 (no) |
GT (1) | GT200600055A (no) |
IL (1) | IL184426A0 (no) |
MA (1) | MA29326B1 (no) |
MY (1) | MY146830A (no) |
NO (1) | NO20074509L (no) |
NZ (1) | NZ556275A (no) |
PE (1) | PE20060999A1 (no) |
TN (1) | TNSN07312A1 (no) |
TW (1) | TW200716081A (no) |
WO (1) | WO2006086456A2 (no) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE551052T1 (de) * | 2004-10-08 | 2012-04-15 | Novartis Ag | Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz |
WO2007051007A2 (en) * | 2005-10-28 | 2007-05-03 | Novartis Ag | Combination of antihypertensives with cholesterol-lowering agent |
AR057882A1 (es) * | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
GB0612540D0 (en) * | 2006-06-23 | 2006-08-02 | Novartis Ag | Galenical formulations of organic compounds |
AR064842A1 (es) | 2007-01-12 | 2009-04-29 | Mazzucco Gavieiro Maria Belen | Pirrolidin-2-onas, y su uso en la preparacion de inhibidores de nep |
TW200838501A (en) | 2007-02-02 | 2008-10-01 | Theravance Inc | Dual-acting antihypertensive agents |
TWI448284B (zh) | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
TWI406850B (zh) | 2007-06-05 | 2013-09-01 | Theravance Inc | 雙效苯并咪唑抗高血壓劑 |
JP2010538071A (ja) | 2007-09-07 | 2010-12-09 | セラヴァンス, インコーポレーテッド | 二重作用性降圧剤 |
AU2008309058B2 (en) * | 2007-09-28 | 2012-08-09 | Novartis Ag | Galenical formulations of Aliskiren and Valsartan |
WO2009040427A1 (en) * | 2007-09-28 | 2009-04-02 | Novartis Ag | Galenical formulations of organic compounds |
BRPI0817586A2 (pt) * | 2007-09-28 | 2015-03-31 | Novartis Ag | Formulações galênicas de compostos orgânicos |
ES2385773T3 (es) | 2007-12-11 | 2012-07-31 | Theravance, Inc. | Derivados de benzoimidazol, de doble acción, y su utilización como agentes antihipertensivos |
EP2297113A1 (en) | 2008-04-29 | 2011-03-23 | Theravance, Inc. | Dual-acting antihypertensive agents |
US8569381B2 (en) | 2008-05-23 | 2013-10-29 | Targacept, Inc. | Combination therapy for the management of hypertension |
US20100093603A1 (en) * | 2008-07-17 | 2010-04-15 | Kenneth Baker | Use of organic compounds |
WO2010011821A2 (en) | 2008-07-24 | 2010-01-28 | Theravance, Inc. | Dual-acting antihypertensive agents |
DE102008059206A1 (de) | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
AR075881A1 (es) * | 2009-03-20 | 2011-05-04 | Novartis Ag | Composicion farmaceutica.metodo de preparacion |
ME01923B (me) | 2009-05-28 | 2015-05-20 | Novartis Ag | Supstituisani derivati aminopropionske kiseline kao inhibitori neprilizina |
ES2582395T3 (es) | 2009-05-28 | 2016-09-12 | Novartis Ag | Derivados aminobutíricos sustituidos como inhibidores de neprilisina |
JP5833000B2 (ja) | 2009-07-07 | 2015-12-16 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | 二重に作用するピラゾール抗高血圧症薬 |
JP2012533626A (ja) | 2009-07-22 | 2012-12-27 | セラヴァンス, インコーポレーテッド | 二重作用オキサゾール降圧剤 |
JO2967B1 (en) * | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
EP2526095A1 (en) | 2010-01-19 | 2012-11-28 | Theravance, Inc. | Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents |
BR112013004164A2 (pt) | 2010-08-23 | 2016-05-10 | Novartis Ag | processo para a preparação de intermediários para a produção de inibidores da nep |
US8673974B2 (en) * | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
US8877815B2 (en) * | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
CA2882771C (en) | 2012-08-24 | 2021-02-23 | Novartis Ag | Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling |
AU2014216417B2 (en) | 2013-02-14 | 2016-05-12 | Novartis Ag | Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy |
EP2956464B1 (en) | 2013-02-14 | 2018-03-28 | Novartis AG | Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors |
CN105348209B (zh) | 2015-12-09 | 2017-12-26 | 浙江天宇药业股份有限公司 | 一种抗心衰药lcz696的制备方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1256692A (en) * | 1991-02-06 | 1992-09-07 | Schering Corporation | Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor |
US5217996A (en) * | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
DE19750529A1 (de) * | 1997-11-14 | 1999-05-20 | Basf Ag | Neue heterocyclisch substituierte alpha-Hydroxycarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten |
US6506785B2 (en) * | 1998-05-22 | 2003-01-14 | Pfizer, Inc. | Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives |
US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
US7468390B2 (en) * | 2002-01-17 | 2008-12-23 | Novartis Ag | Methods of treatment and pharmaceutical composition |
NZ533968A (en) * | 2002-01-17 | 2006-10-27 | Novartis Ag | Pharmaceutical compositions comprising valsartan and nep inhibitors |
JP5288678B2 (ja) * | 2002-05-17 | 2013-09-11 | ノバルティス アーゲー | レニンインヒビター、カルシウムチャネルブロッカーおよび利尿薬を含む医薬組成物 |
GB0212412D0 (en) * | 2002-05-29 | 2002-07-10 | Novartis Ag | Combination of organic compounds |
CL2004000544A1 (es) * | 2003-03-18 | 2005-01-28 | Pharmacia Corp Sa Organizada B | Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati |
CL2004000545A1 (es) * | 2003-03-18 | 2005-01-28 | Pharmacia Corp Sa Organizada B | Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul |
US20040214804A1 (en) * | 2003-04-25 | 2004-10-28 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and an anti-obesity agent |
-
2006
- 2006-02-07 MY MYPI20060499A patent/MY146830A/en unknown
- 2006-02-09 AR ARP060100468A patent/AR053809A1/es not_active Application Discontinuation
- 2006-02-09 EP EP06734563A patent/EP1863467A2/en not_active Withdrawn
- 2006-02-09 PE PE2006000152A patent/PE20060999A1/es not_active Application Discontinuation
- 2006-02-09 KR KR1020077018445A patent/KR20070102544A/ko not_active Application Discontinuation
- 2006-02-09 JP JP2007555186A patent/JP2008530101A/ja active Pending
- 2006-02-09 CA CA002596485A patent/CA2596485A1/en not_active Abandoned
- 2006-02-09 AU AU2006212772A patent/AU2006212772B2/en not_active Ceased
- 2006-02-09 US US11/813,530 patent/US20080119557A1/en not_active Abandoned
- 2006-02-09 BR BRPI0606996-7A patent/BRPI0606996A2/pt not_active IP Right Cessation
- 2006-02-09 NZ NZ556275A patent/NZ556275A/en not_active IP Right Cessation
- 2006-02-09 WO PCT/US2006/004401 patent/WO2006086456A2/en active Application Filing
- 2006-02-10 TW TW095104610A patent/TW200716081A/zh unknown
- 2006-02-10 GT GT200600055A patent/GT200600055A/es unknown
-
2007
- 2007-07-05 IL IL184426A patent/IL184426A0/en unknown
- 2007-08-10 TN TNP2007000312A patent/TNSN07312A1/en unknown
- 2007-09-06 NO NO20074509A patent/NO20074509L/no not_active Application Discontinuation
- 2007-09-10 MA MA30209A patent/MA29326B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
MY146830A (en) | 2012-09-28 |
US20080119557A1 (en) | 2008-05-22 |
CA2596485A1 (en) | 2006-08-17 |
NZ556275A (en) | 2011-04-29 |
TW200716081A (en) | 2007-05-01 |
JP2008530101A (ja) | 2008-08-07 |
KR20070102544A (ko) | 2007-10-18 |
TNSN07312A1 (en) | 2008-12-31 |
GT200600055A (es) | 2006-09-07 |
WO2006086456A2 (en) | 2006-08-17 |
MA29326B1 (fr) | 2008-03-03 |
WO2006086456A3 (en) | 2007-11-15 |
AU2006212772A1 (en) | 2006-08-17 |
AU2006212772B2 (en) | 2009-06-11 |
AR053809A1 (es) | 2007-05-23 |
IL184426A0 (en) | 2007-10-31 |
BRPI0606996A2 (pt) | 2009-07-28 |
PE20060999A1 (es) | 2006-11-21 |
EP1863467A2 (en) | 2007-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20074509L (no) | Kombinasjon av organiske forbindelser | |
WO2007056324A3 (en) | Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent | |
NO20075344L (no) | Metforminbaserte fremgangsmater og utforminger for behandling av kronisk forstoppelse | |
WO2008050329A3 (en) | Novel sirnas and methods of use thereof | |
WO2005070463A3 (en) | Compositions comprising (s)-amlodipine malate and an angiotensin receptor blocker and methods of their use | |
NO20070910L (no) | Pyrrolderivater som farmasoytiske middel | |
WO2006059245A3 (en) | Compounds for the treatment of cns and amyloid associated diseases | |
NO20044562L (no) | Fremgangsmater for behandling av tarmslyng | |
WO2006044694A3 (en) | Methods and compositions for treating a disease condition in a subject | |
JP2008508279A5 (no) | ||
WO2007088489A3 (en) | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same | |
NO20083836L (no) | N-hydroksyakrylamidforbindelser | |
WO2007120972A3 (en) | Method to treat sickle cell disease | |
WO2006020680A3 (en) | Heterocyclic compounds as pharmaceutical agents | |
WO2008087491A8 (en) | Method for treating or preventing symptoms of hormonal variations | |
WO2008059370A8 (en) | Substituted bicyclocarboxyamide compounds | |
WO2008050199A3 (en) | Substituted phenylmethyl bicyclocarboxyamide compounds | |
MX2007004020A (es) | Uso de inhibidores de renina para la prevencion o tratamiento de disfuncion diastolica o falla cardiaca diastolica. | |
WO2006061715A3 (en) | Methylene inhibitors of matrix metalloproteinase | |
WO2007092469A3 (en) | Combination of organic compounds | |
WO2006031782A3 (en) | Salvinorin derivatives as opioid receptor ligands | |
WO2007006790A3 (en) | Combination of a dpp-iv inhibitor and a cannabinoid cb1 receptor antagonist | |
WO2003051290A3 (en) | Treating b-cell mediated diseases by modulating dr6 activity | |
NO20070127L (no) | Fremgangsmate for behandling av granuloma annulare eller sarkoid | |
CL2003002292A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de acido carboxilico, uno o mas compuestos terapeuticamente activos y un diluyente farmacologicamente aceptable; y su uso para tratar una enfermedad inflamatoria. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |